Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Gasi, Delila ^a   van der Korput, Hetty A ^a   Douben, Hannie C ^a   de Klein, Annelies ^a   de Ridder, Corrina M ^a   van Weerden, Wytske M ^a   Trapman, Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HYBRID PROTEIN; PROTEIN EST14 TRANSCRIPTION FACTOR ETV1 FUSION PROTEIN; TRANSCRIPTION FACTOR ER81; UNCLASSIFIED DRUG; UNTRANSLATED RNA; DNA BINDING PROTEIN; ETV1 PROTEIN, HUMAN; ISOPROTEIN; RNA; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHROMOSOME 10; CHROMOSOME 14; CHROMOSOME 4; CHROMOSOME 7; CHROMOSOME MAP; COMPLEX FORMATION; CONTROLLED STUDY; EXON; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LINKAGE ANALYSIS; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; GENE EXPRESSION REGULATION; GENETICS; HUMAN CHROMOSOME; PROSTATE TUMOR;

CHROMOSOMES, HUMAN; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 79551528365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016332     Document Type: Article

References (14)

1. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
2. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
3. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, et al. (2006) TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in latestage androgen receptor-negative prostate cancer. Cancer Res 66: 10658-10663.
4. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, et al. (2006) TMPRSS2-ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Canser Res 66: 8337-8341.
5. Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66: 8347-8351.
6. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulstron D, et al. (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396-3400.
7. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, et al. (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68: 73-80.
8. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
9. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, et al. (2008) Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 99: 314-320.
10. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DS, Zielvan der Made A, et al. (2008) Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68: 7541-7549.
11. Wasylyk B, Hahn SL, Giovane A (1993) The Ets family of transcription factors. Eur J Biochem 211: 7-18.
12. Oikawa T, Yamada T (2003) Molecular biology of the Ets family of transcription factors. Gene 303: 11-34.
13. Seth A, Watson DK (2005) ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478.
14. Eussen BH, van de Laar I, Douben H, van Kempen L, Hochstenbach R, et al. (2007) A familial inverted duplication 2q33-q34 identified and delinieated by multiple cytogenetic techniques. Eur J Med. Genet 50: 112-119.